Clinical Trial Update: MK0859 Dose-Ranging Study (0859-003) [Phase 2]

View source ↗

Summary

Merck's Phase 2 dose-ranging study of MK0859 (NCT00325455) for hypercholesterolemia and mixed hyperlipidemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Hyperlipidemia

Drugs mentioned

• MK0859

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolemia, Mixed Hyperlipemia | Phase 2 | Status: TERMINATED